Follow us on:

AZN

AstraZeneca’s Fasenra phase III OSTRO trial met co-primary endpoints

September 10, 2020

AstraZeneca’s Farxiga reduces CKD progression and risk of death

September 1, 2020

AstraZeneca Phase I clinical trial initiated for COVID-19 monoclonal antibody

August 25, 2020

AstraZeneca’s Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use

August 18, 2020

AstraZeneca Calquence recommended for approval in the EU

July 27, 2020

AstraZeneca’s Breztri Aerosphere approved in the US for COPD

July 24, 2020

AstraZeneca’s Brilinta granted FDA Priority Review for stroke

July 9, 2020

AstraZeneca’s Lynparza receives EU approval for pancreatic cancer

July 8, 2020

AstraZeneca’s selumetinib granted orphan drug designation in Japan

June 30, 2020

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s COVID-19 vaccine

June 15, 2020

AstraZeneca Brilinta approved in the US by FDA

June 1, 2020

AstraZeneca Tagrisso demonstrates unprecedented disease-free survival

May 29, 2020

AstraZeneca Enhertu granted Orphan Drug Designation in the US for gastric cancer

May 22, 2020

AstraZeneca concludes first agreements for University of Oxford’s potential new COVID-19 vaccine

May 21, 2020

AstraZeneca Lynparza approved in the US by FDA for prostate cancer

May 20, 2020

AstraZeneca’s Bevespi Aerosphere approved in China for patients with COPD

May 18, 2020

AstraZeneca Enhertu granted Breakthrough Therapy Designation in the US

May 11, 2020

AstraZeneca Farxiga approved in the US for the treatment of heart failure

May 6, 2020

AstraZeneca’s Lynparza demonstrates overall survival benefit in prostate cancer

April 24, 2020

AstraZeneca unblind Phase III ADAURA trial much earlier than expected

April 14, 2020

News and Interview Alerts

Company Presentations

Immotion Group

Immotion Group the exciting world of VR Location and Home Based Entertainment (Interview)

Symphony Environmental Technologies

Symphony Environmental Technologies 2020 Results Presentation

Anexo Group

Anexo Group Final Results Investor Presentation 2021

STM Group

STM Group Final Results Investor Presentation

Q&As

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

23 January 2026

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

TEAM plc Mark Clubb Executive Chairman Sets Sights on £2 billion as UCITS Launch Fuels Global Growth

ICG Enterprise Trust: Inside the Numbers Driving Outperformance in Private Equity (Video)

BrokerTalk

Arbuthnot Banking Group

Arbuthnot Banking Group Demonstrates Capital Discipline and Strategic Progress, Shore Capital Notes

24 July 2025

CyanConnode

CyanConnode: A Stronger Foundation and Growing Momentum – Highlights Panmure Liberum

23 July 2025

Synetics Plc

Synectics Maintains Strong Momentum with Promising FY25 Outlook – Shore Capital

22 July 2025

Pharos Energy

Pharos Energy Reaffirms Production Guidance and Strengthens Balance Sheet – Shore Capital

21 July 2025

Funds

Global Opportunities Trust

Global Opportunities Trust: Cash builds as valuations rise | New Research

28 January 2026

Fidelity

Fidelity Emerging Markets Ltd doubles index performance with 56% share price growth in 2025

27 January 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

XPS Pensions Group PLC (XPS.L): Analyst Consensus Signals a 29% Upside Potential for Investors

30 January 2026

Vesuvius PLC (VSVS.L) Stock Analysis: Why This UK Steel Giant Offers a 5.06% Dividend Yield with a 2.59% Potential Upside

30 January 2026

ZIGUP PLC ORD 50P (ZIG.L) Stock Analysis: A 31% Upside Potential and Robust Dividend Yield

30 January 2026

VINACAPITAL VIETNAM OPPORTUNITY (VOF.L) Stock Analysis: Exploring a 21.95% Potential Upside

30 January 2026

THG PLC ORD GBP0.005 (THG.L) Stock Analysis: Exploring a 42.62% Potential Upside Amidst Market Challenges

30 January 2026

January 31, 2025

AstraZeneca’s Fasenra phase III OSTRO trial met co-primary endpoints

September 10, 2020

AstraZeneca’s Farxiga reduces CKD progression and risk of death

September 1, 2020

AstraZeneca Phase I clinical trial initiated for COVID-19 monoclonal antibody

August 25, 2020

AstraZeneca’s Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use

August 18, 2020

AstraZeneca Calquence recommended for approval in the EU

July 27, 2020

AstraZeneca’s Breztri Aerosphere approved in the US for COPD

July 24, 2020

AstraZeneca’s Brilinta granted FDA Priority Review for stroke

July 9, 2020

AstraZeneca’s Lynparza receives EU approval for pancreatic cancer

July 8, 2020

AstraZeneca’s selumetinib granted orphan drug designation in Japan

June 30, 2020

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s COVID-19 vaccine

June 15, 2020

AstraZeneca Brilinta approved in the US by FDA

June 1, 2020

AstraZeneca Tagrisso demonstrates unprecedented disease-free survival

May 29, 2020

AstraZeneca Enhertu granted Orphan Drug Designation in the US for gastric cancer

May 22, 2020

AstraZeneca concludes first agreements for University of Oxford’s potential new COVID-19 vaccine

May 21, 2020

AstraZeneca Lynparza approved in the US by FDA for prostate cancer

May 20, 2020

AstraZeneca’s Bevespi Aerosphere approved in China for patients with COPD

May 18, 2020

AstraZeneca Enhertu granted Breakthrough Therapy Designation in the US

May 11, 2020

AstraZeneca Farxiga approved in the US for the treatment of heart failure

May 6, 2020

AstraZeneca’s Lynparza demonstrates overall survival benefit in prostate cancer

April 24, 2020

AstraZeneca unblind Phase III ADAURA trial much earlier than expected

April 14, 2020

News and Interview Alerts

Company Presentations

Immotion Group

Immotion Group the exciting world of VR Location and Home Based Entertainment (Interview)

Symphony Environmental Technologies

Symphony Environmental Technologies 2020 Results Presentation

Anexo Group

Anexo Group Final Results Investor Presentation 2021

STM Group

STM Group Final Results Investor Presentation

Q&As

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

Green News

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

23 January 2026

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest interviews

TEAM plc Mark Clubb Executive Chairman Sets Sights on £2 billion as UCITS Launch Fuels Global Growth

ICG Enterprise Trust: Inside the Numbers Driving Outperformance in Private Equity (Video)

Broker Talk

Arbuthnot Banking Group

Arbuthnot Banking Group Demonstrates Capital Discipline and Strategic Progress, Shore Capital Notes

24 July 2025

CyanConnode

CyanConnode: A Stronger Foundation and Growing Momentum – Highlights Panmure Liberum

23 July 2025

Synetics Plc

Synectics Maintains Strong Momentum with Promising FY25 Outlook – Shore Capital

22 July 2025

Pharos Energy

Pharos Energy Reaffirms Production Guidance and Strengthens Balance Sheet – Shore Capital

21 July 2025

Funds

Global Opportunities Trust

Global Opportunities Trust: Cash builds as valuations rise | New Research

28 January 2026

Fidelity

Fidelity Emerging Markets Ltd doubles index performance with 56% share price growth in 2025

27 January 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

XPS Pensions Group PLC (XPS.L): Analyst Consensus Signals a 29% Upside Potential for Investors

30 January 2026

Vesuvius PLC (VSVS.L) Stock Analysis: Why This UK Steel Giant Offers a 5.06% Dividend Yield with a 2.59% Potential Upside

30 January 2026

ZIGUP PLC ORD 50P (ZIG.L) Stock Analysis: A 31% Upside Potential and Robust Dividend Yield

30 January 2026

VINACAPITAL VIETNAM OPPORTUNITY (VOF.L) Stock Analysis: Exploring a 21.95% Potential Upside

30 January 2026

THG PLC ORD GBP0.005 (THG.L) Stock Analysis: Exploring a 42.62% Potential Upside Amidst Market Challenges

30 January 2026

AZN

injection

AstraZeneca’s Fasenra phase III OSTRO trial met co-primary endpoints

10 September 2020

AstraZeneca

AstraZeneca’s Farxiga reduces CKD progression and risk of death

1 September 2020

COVID19

AstraZeneca Phase I clinical trial initiated for COVID-19 monoclonal antibody

25 August 2020

AstraZeneca

AstraZeneca’s Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use

18 August 2020

medication

AstraZeneca Calquence recommended for approval in the EU

27 July 2020

Inhaler

AstraZeneca’s Breztri Aerosphere approved in the US for COPD

24 July 2020

AstraZeneca

AstraZeneca’s Brilinta granted FDA Priority Review for stroke

9 July 2020

AstraZeneca

AstraZeneca’s Lynparza receives EU approval for pancreatic cancer

8 July 2020

AstraZeneca

AstraZeneca’s selumetinib granted orphan drug designation in Japan

30 June 2020

coronavirus vaccine

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s COVID-19 vaccine

15 June 2020

biopharmaceutical

AstraZeneca Brilinta approved in the US by FDA

1 June 2020

AstraZeneca

AstraZeneca Tagrisso demonstrates unprecedented disease-free survival

29 May 2020

biopharmaceutical

AstraZeneca Enhertu granted Orphan Drug Designation in the US for gastric cancer

22 May 2020

coronavirus vaccine

AstraZeneca concludes first agreements for University of Oxford’s potential new COVID-19 vaccine

21 May 2020

AstraZeneca

AstraZeneca Lynparza approved in the US by FDA for prostate cancer

20 May 2020

chronic obstructive pulmonary disease

AstraZeneca’s Bevespi Aerosphere approved in China for patients with COPD

18 May 2020

intravenous (IV) line

AstraZeneca Enhertu granted Breakthrough Therapy Designation in the US

11 May 2020

AstraZeneca

AstraZeneca Farxiga approved in the US for the treatment of heart failure

6 May 2020

AstraZeneca

AstraZeneca’s Lynparza demonstrates overall survival benefit in prostate cancer

24 April 2020

AstraZeneca

AstraZeneca unblind Phase III ADAURA trial much earlier than expected

14 April 2020

Latest Interviews

TEAM plc Mark Clubb Executive Chairman Sets Sights on £2 billion as UCITS Launch Fuels Global Growth

7 August 2025

ICG Enterprise Trust: Inside the Numbers Driving Outperformance in Private Equity (Video)

31 July 2025

FTSE 100 News

FTSE 250 News

Ruffer Investment Company

Prediction markets move into the mainstream as trading surges | Ruffer Investment Company

12 December 2025

News and Interview Alerts

Company Presentations

Immotion Group

Immotion Group the exciting world of VR Location and Home Based Entertainment (Interview)

7 June 2021

Symphony Environmental Technologies

Symphony Environmental Technologies 2020 Results Presentation

24 May 2021

Anexo Group

Anexo Group Final Results Investor Presentation 2021

24 May 2021

STM Group

STM Group Final Results Investor Presentation

20 May 2021

Q&As

Hardman & Co

NB Private Equity Partners 2025 CMD: good returns from low-risk PE model

10 December 2025

Real Estate Credit Investments (RECI): Investor Day: opportunities aplenty

2 December 2025

Volta Finance: Liquid access to outperforming private credit

6 October 2025

Real Estate Credit Investments: What RECI brings to investors

15 September 2025

Chesnara Plc: Showing good operational progress

8 September 2025

BrokerTalk

Arbuthnot Banking Group

Arbuthnot Banking Group Demonstrates Capital Discipline and Strategic Progress, Shore Capital Notes

24 July 2025

CyanConnode

CyanConnode: A Stronger Foundation and Growing Momentum – Highlights Panmure Liberum

23 July 2025

Synetics Plc

Synectics Maintains Strong Momentum with Promising FY25 Outlook – Shore Capital

22 July 2025

Pharos Energy

Pharos Energy Reaffirms Production Guidance and Strengthens Balance Sheet – Shore Capital

21 July 2025

FTSE 100

Funds

Global Opportunities Trust

Global Opportunities Trust: Cash builds as valuations rise | New Research

28 January 2026

Fidelity

Fidelity Emerging Markets Ltd doubles index performance with 56% share price growth in 2025

27 January 2026

View all Funds, Market Insights and news >>

Green News

Ilika Plc: Solid-State Breakthroughs Put Stereax and Goliath in the Spotlight (Video)

23 January 2026

Drax expands FlexGen platform with Flexitricity acquisition

21 January 2026

View all Sustainable sectors, Plcs and news >>

UK Broker Ratings

XPS Pensions Group PLC (XPS.L): Analyst Consensus Signals a 29% Upside Potential for Investors

30 January 2026

Vesuvius PLC (VSVS.L) Stock Analysis: Why This UK Steel Giant Offers a 5.06% Dividend Yield with a 2.59% Potential Upside

30 January 2026

ZIGUP PLC ORD 50P (ZIG.L) Stock Analysis: A 31% Upside Potential and Robust Dividend Yield

30 January 2026

VINACAPITAL VIETNAM OPPORTUNITY (VOF.L) Stock Analysis: Exploring a 21.95% Potential Upside

30 January 2026

THG PLC ORD GBP0.005 (THG.L) Stock Analysis: Exploring a 42.62% Potential Upside Amidst Market Challenges

30 January 2026